Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced that it will present new clinical study data at the ESMO Virtual Congress 2021 from September 16-21, 2021. The presentation will focus on dual targeting PD-1 and BRD4 using the company's proprietary INTASYL self-delivering RNAi platform, aiming to elicit persistent anti-tumor immunity following tumor resolution. The abstract number for this presentation is #4154. Archived details will be available on the Company's website in the Investors section.
- None.
- None.
MARLBOROUGH, Mass., Aug. 31, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held from September 16-21, 2021.
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Details are as follows: | |
Event: | ESMO Virtual Congress 2021 |
Title: | Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors |
Authors: | Benjamin Cuiffo, et al. |
Abstract Number: | #4154 |
Date: | September 16-21, 2021 |
An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company's website (click here).
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by the ongoing coronavirus pandemic, the development of our product candidates, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, results from our preclinical and clinical activities, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com
Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-upcoming-data-presentation-at-the-esmo-virtual-congress-2021-301365371.html
SOURCE Phio Pharmaceuticals Corp.
FAQ
What will Phio Pharmaceuticals present at the ESMO Virtual Congress 2021?
When is the ESMO Virtual Congress 2021?
What is the abstract number for Phio Pharmaceuticals' presentation?
Where can I find Phio Pharmaceuticals' archived presentation?
What is the focus of Phio Pharmaceuticals' research?
